Switch theme
Sign up to access all valuation multiples
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
2018
647
LTM Revenue $28.4M
LTM EBITDA -$213M
$6.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Autolus Therapeutics has a last 12-month revenue (LTM) of $28.4M and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, Autolus Therapeutics achieved revenue of $10.1M and an EBITDA of -$202M.
Autolus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Autolus Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.4M | XXX | $10.1M | XXX | XXX | XXX |
| Gross Profit | $4.8M | XXX | -$1.3M | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | -13% | XXX | XXX | XXX |
| EBITDA | -$213M | XXX | -$202M | XXX | XXX | XXX |
| EBITDA Margin | -749% | XXX | -1997% | XXX | XXX | XXX |
| EBIT | -$234M | XXX | -$241M | XXX | XXX | XXX |
| EBIT Margin | -824% | XXX | -2379% | XXX | XXX | XXX |
| Net Profit | -$225M | XXX | -$221M | XXX | XXX | XXX |
| Net Margin | -794% | XXX | -2180% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Autolus Therapeutics's stock price is $2.
Autolus Therapeutics has current market cap of $466M, and EV of $6.9M.
See Autolus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.9M | $466M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Autolus Therapeutics has market cap of $466M and EV of $6.9M.
Autolus Therapeutics's trades at 0.7x EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate Autolus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Autolus Therapeutics has a P/E ratio of -2.1x.
See valuation multiples for Autolus Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $466M | XXX | $466M | XXX | XXX | XXX |
| EV (current) | $6.9M | XXX | $6.9M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -2.1x | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAutolus Therapeutics's last 12 month revenue growth is 209%
Autolus Therapeutics's revenue per employee in the last FY averaged $16K, while opex per employee averaged $0.4M for the same period.
Autolus Therapeutics's rule of 40 is -9024% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Autolus Therapeutics's rule of X is -228% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Autolus Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 209% | XXX | 265% | XXX | XXX | XXX |
| EBITDA Margin | -749% | XXX | -1997% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -9024% | XXX | -1789% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -228% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1368% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2367% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autolus Therapeutics acquired XXX companies to date.
Last acquisition by Autolus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Autolus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Autolus Therapeutics founded? | Autolus Therapeutics was founded in 2018. |
| Where is Autolus Therapeutics headquartered? | Autolus Therapeutics is headquartered in United States of America. |
| How many employees does Autolus Therapeutics have? | As of today, Autolus Therapeutics has 647 employees. |
| Who is the CEO of Autolus Therapeutics? | Autolus Therapeutics's CEO is Dr. Christian Itin, PhD.. |
| Is Autolus Therapeutics publicy listed? | Yes, Autolus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Autolus Therapeutics? | Autolus Therapeutics trades under AUTL ticker. |
| When did Autolus Therapeutics go public? | Autolus Therapeutics went public in 2018. |
| Who are competitors of Autolus Therapeutics? | Similar companies to Autolus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Autolus Therapeutics? | Autolus Therapeutics's current market cap is $466M |
| What is the current revenue of Autolus Therapeutics? | Autolus Therapeutics's last 12 months revenue is $28.4M. |
| What is the current revenue growth of Autolus Therapeutics? | Autolus Therapeutics revenue growth (NTM/LTM) is 209%. |
| What is the current EV/Revenue multiple of Autolus Therapeutics? | Current revenue multiple of Autolus Therapeutics is 0.2x. |
| Is Autolus Therapeutics profitable? | Yes, Autolus Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Autolus Therapeutics? | Autolus Therapeutics's last 12 months EBITDA is -$213M. |
| What is Autolus Therapeutics's EBITDA margin? | Autolus Therapeutics's last 12 months EBITDA margin is -749%. |
| What is the current EV/EBITDA multiple of Autolus Therapeutics? | Current EBITDA multiple of Autolus Therapeutics is -0.0x. |
| What is the current FCF of Autolus Therapeutics? | Autolus Therapeutics's last 12 months FCF is -$205M. |
| What is Autolus Therapeutics's FCF margin? | Autolus Therapeutics's last 12 months FCF margin is -722%. |
| What is the current EV/FCF multiple of Autolus Therapeutics? | Current FCF multiple of Autolus Therapeutics is -0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
